The removal from plasma of chylomicrons and remnants is reduced in heterozygous familial hypercholesterolemia subjects with identified LDL receptor mutations: Study with artificial emulsions

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 268-274

  Carneiro, Marcia M ^a   Miname, Marcio H ^a   Gagliardi, Ana C ^a   Pereira, Carolina ^a   Pereira, Alexandre C ^a   Krieger, Jose E ^a   Maranhão, Raul C ^a   Santos, Raul D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chylomicrons; Emulsions; Familial hypercholesterolemia; LDL receptor mutations; Triglyceride rich lipoproteins

Indexed keywords

CARBON 14; CHOLESTEROL; CHOLESTEROL ESTER; CHYLOMICRON REMNANT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; TRIOLEIN; TRITIUM;

ADULT; AGED; APHERESIS; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EMULSION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; ISOTOPE LABELING; KINETICS; LIPOLYSIS; MALE; MUTATION; PRIORITY JOURNAL; RADIOISOTOPE DECAY; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BRAZIL; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL ESTERS; CHYLOMICRON REMNANTS; CHYLOMICRONS; EMULSIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INJECTIONS, INTRAVENOUS; LIPOLYSIS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; RECEPTORS, LDL; TRIOLEIN; TRITIUM;

EID: 84857029783     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.033     Document Type: Article

References (39)

1. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004, 173:55-68.
2. Cooper A.D. Hepatic uptake of chylomicron remnants. J Lipid Res 1997, 38:2173-2192.
3. Mamo J.C., Proctor S.D., Smith D. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998, 141(Suppl. 1):S63-S69.
4. Proctor S.D., Mamo J.C. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall - evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest 1998, 28:497-503.
5. Rubinsztein D.C., Cohen J.C., Berger G.M., van der Westhuyzen D.R., Coetzee G.A., Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest 1990, 86:1306-1312.
6. Kita T., Goldstein J.L., Brown M.S., Watanabe Y., Hornick C.A., Havel R.J. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci U S A 1982, 79:3623-3627.
7. Bowler A., Redgrave T.G., Mamo J.C. Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperslipidaemic rabbits is defective. Lack of evidence for an independent chylomicron-remnant receptor. Biochem J 1991, 276(Pt 2):381-386.
8. Cabezas M.C., de Bruin T.W., Westerveld H.E., Meijer E., Erkelens D.W. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J Intern Med 1998, 244:299-307.
9. Watts G.F., Barrett P.H., Marais A.D., et al. Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test. Atherosclerosis 2001, 157:519-523.
10. Tremblay A.J., Lamarche B., Ruel I., et al. Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation. Atherosclerosis 2004, 172:367-373.
11. Redgrave T.G., Maranhao R.C. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim Biophys Acta 1985, 835:104-112.
12. Maranhão R.C., Feres M.C., Martins M.T., et al. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis 1996, 126:15-25.
13. Santos R.D., Sposito A.C., Ventura L.I., Cesar L.A., Ramires J.A., Maranhão R.C. Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am J Cardiol 2000, 85:1163-1166.
14. Sposito A.C., Santos R.D., Hueb W., et al. LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease. Atherosclerosis 2002, 161:447-453.
15. Sposito A.C., Santos R.D., Amâncio R.F., Ramires J.A., Chapman M.J., Maranhão R.C. Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins. Atherosclerosis 2003, 166:311-321.
16. Sposito A.C., Ventura L.I., Vinagre C.G., et al. Delayed intravascular catabolism of chylomicron-like emulsions is an independent predictor of coronary artery disease. Atherosclerosis 2004, 176:397-403.
17. Sposito A.C., Lemos P.A., Santos R.D., et al. Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study. J Am Coll Cardiol 2004, 43:2225-2232.
18. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993, 72:171-176.
19. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
20. Redgrave T.G., Roberts D.C.K., West C.E. Separation of plasma lipoprotein by density-gradient ultracentrifugation. Anal Biochem 1975, 65:42-49.
21. Redgrave T.G., Zech L.A. A kinetic model of chylomicron core lipid metabolism in rats: the effect of a single meal. J Lipid Res 1987, 28:473-482.
22. 137C transfer rates in marine organisms and dose in man. J Radioanal Nucl Chem 1998, 232:233-236.
23. César T.B., Oliveira M.R., Mesquita C.H., Maranhão R.C. High cholesterol intake modifies chylomicron metabolism in normolipidemic young men. J Nutr 2006, 136:971-976.
24. Dietschy J.M. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr 1998, 128:444S-448S.
25. Reihnér E., Rudling M., Stalberg D., et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990, 323:224-228.
26. Santos R.D., Ventura L.I., Spósito A.C., Schreiber R., Ramires J.A., Maranhão R.C. The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. Cardiovasc Res 2001, 49:456-465.
27. Sposito A.C., Maranhão R.C., Vinagre C.G., Santos R.D., Ramires J.A. Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis 2001, 154:455-461.
28. Soskaa V., Freibergerb T., Cifkovac R., et al. HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: data from the MedPed CZ database and the Czech population. Clin Chim Acta 2011, 412:920-924.
29. Cummings M.H., Watts G.F., Umpleby M., Hennessy T.R., Quiney J.R., Sonksen P.H. Increased hepatic secretion of VLDL apolipoprotein B-100 in heterozygous familial hypercholesterolemia: a stable isotope study. Atherosclerosis 1995, 113:79-89.
30. Millar J.S., Maugeais C., Ikewaki K., et al. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol 2005, 25:560-565.
31. Hussain M.M., Innerarity T.L., Brecht W.J., Mahley R.W. Chylomicron metabolism in normal, cholesterol-fed, and Watanabe heritable hyperlipidaemic rabbits. Saturation of the sequestration step of the remnant clearance pathway. J Biol Chem 1995, 270:8578-8587.
32. Choi S.Y., Fong L.G., Kirven M.J., Cooper A.D. Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo. J Clin Invest 1991, 88:1173-1181.
33. Herz J., Qiu S.Q., Oesterle A., DeSilva H.V., Shafi S., Havel R.J. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1995, 92:4611-4615.
34. Eriksson M., Angelin B., Henriksson P., Ericsson S., Vitols S., Berglund L. Metabolism of lipoprotein remnants in humans. Studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor. Arterioscler Thromb 1991, 11:827-837.
35. Mamo J.C., Smith D., Yu K.C., et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemia. Eur J Clin Invest 1998, 28:379-384.
36. Rensen P.C., Herijgers N., Netscher M.H., Meskers S.C., van Eck M., van Berkel T.J. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res 1997, 38:1070-1084.
37. Lossow W.J., Lindgren F.T., Murchio J.C., Stevens G.K. Particle size and protein content of six fractions of the S, >20 plasma lipoproteins isolated by density gradient centrifugation. J Lipid Res 1969, 10:68-76.
38. Hayashi H., Fujimoto K., Cardelli J.A., Nutting D.F., Bergsted S., Tso P. Fat feeding increases size, but not number, of chylomicrons produced by the small intestine. Am J Physiol 1990, 259:G709-G719.
39. Twickler T.B., Dallinga-Thie G.M., de Valk H.W., Schreuder P.C., Jansen H., Cabezas M.C. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000, 20:2422-2427.